Genelux Corp. (GNLX)
2.56
+0.04
(+1.59%)
USD |
NASDAQ |
Oct 02, 16:00
2.56
0.00 (0.00%)
After-Hours: 20:00
Genelux Enterprise Value : 99.22M for Oct. 2, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 02, 2026 | 99.22M |
| October 01, 2026 | 97.41M |
| September 30, 2026 | 97.86M |
| September 29, 2026 | 94.25M |
| September 28, 2026 | 95.16M |
| September 25, 2026 | 95.61M |
| September 24, 2026 | 93.35M |
| September 23, 2026 | 97.19M |
| September 22, 2026 | 101.47M |
| September 21, 2026 | 99.22M |
| September 18, 2026 | 97.86M |
| September 17, 2026 | 97.86M |
| September 16, 2026 | 89.29M |
| September 15, 2026 | 95.16M |
| September 14, 2026 | 98.31M |
| September 11, 2026 | 96.06M |
| September 10, 2026 | 95.61M |
| September 09, 2026 | 97.41M |
| September 08, 2026 | 98.31M |
| September 04, 2026 | 93.80M |
| September 03, 2026 | 97.41M |
| September 02, 2026 | 98.76M |
| September 01, 2026 | 101.02M |
| August 31, 2026 | 101.70M |
| August 28, 2026 | 103.73M |
| Date | Value |
|---|---|
| August 27, 2026 | 113.65M |
| August 26, 2026 | 106.88M |
| August 25, 2026 | 106.43M |
| August 24, 2026 | 106.43M |
| August 21, 2026 | 106.43M |
| August 20, 2026 | 107.33M |
| August 19, 2026 | 104.63M |
| August 18, 2026 | 101.02M |
| August 17, 2026 | 105.53M |
| August 14, 2026 | 107.33M |
| August 13, 2026 | 102.37M |
| August 12, 2026 | 105.53M |
| August 11, 2026 | 103.27M |
| August 10, 2026 | 106.43M |
| August 07, 2026 | 103.73M |
| August 06, 2026 | 105.53M |
| August 05, 2026 | 96.96M |
| August 04, 2026 | 110.94M |
| August 03, 2026 | 118.16M |
| July 31, 2026 | 116.35M |
| July 30, 2026 | 121.32M |
| July 29, 2026 | 111.39M |
| July 28, 2026 | 115.45M |
| July 27, 2026 | 116.81M |
| July 24, 2026 | 114.10M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Arcutis Biotherapeutics, Inc. | 3.035B |
| ACADIA Pharmaceuticals, Inc. | 2.551B |
| Alnylam Pharmaceuticals, Inc. | 29.06B |
| Savara, Inc. | 845.34M |
| Vericel Corp. | 1.987B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -9.471M |
| Total Expenses (Quarterly) | 9.471M |
| EPS Diluted (Quarterly) | -0.2107 |
| Earnings Yield | -33.90% |
| Normalized Earnings Yield | -33.90 |